7-methoxyquinoline-8-carbaldehyde | 82060-67-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-methoxyquinoline-8-carbaldehyde
• CAS: 82060-67-1
• 化学式: C₁₁H₉NO₂
• 分子量: 187.198
• InChiKey: FUNBQTYAAUCTPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-methoxyquinoline-8-carbaldehyde 生成 5-(7-Methoxy-8-quinolyl)oxazolidin-4-one-2-thione
  参考文献：
  名称：

  Hypoglycemic 5-substituted oxazolidine-2,4-diones

  摘要：

  低血糖性的5-色基苯基、2,3-二氢-5-苯并[b]呋喃基、5-吡啶基、5-喹啉基、5-吡咯基、5-吲哚基、5-噻唑基、5-噁唑基、5-异噻唑基和5-异噁唑基噁唑烷-2,4-二酮及其药用可接受的盐；某些3-酰化衍生物；一种用于治疗高血糖动物的方法；以及在制备上述化合物中有用的中间体。

  公开号：

  US04342771A1

文献信息

• [EN] PYRIMIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRIMIDINE
  申请人：IDORSIA PHARMACEUTICALS LTD

  公开号：WO2018210992A1

  公开（公告）日：2018-11-22

  The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R5b, and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

  本发明涉及式(I)的嘧啶衍生物，其中(R1)n，R3，R4a，R5b和Ar1如描述中所述，及其用于通过调节肿瘤中的免疫系统的再激活来治疗癌症的免疫应答。本发明进一步涉及新颖的苯并呋喃和苯并噻吩衍生物式(III)及其作为药物的使用，其制备方法，药用可接受的盐，以及作为药物的使用，包括含有式(I)的一个或多个化合物的药物组合物，尤其是它们作为前列腺素2受体EP2和/或EP4的调节剂的使用。
• NOVEL OXAZOLIDINONE DERIVIATIVES
  申请人：Aissaoui Hamed

  公开号：US20120101111A1

  公开（公告）日：2012-04-26

  The present invention relates to oxazolidinone derivatives of formula (I) wherein Y, R 3 and R 4 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.

  本发明涉及式(I)的噁唑烷酮衍生物，其中Y、R3和R4如描述中所述，以及它们的制备方法，它们的药用盐，以及它们作为药物的用途，包括含有一个或多个式(I)化合物的药物组合物，特别是它们作为促进睡眠的药物受体拮抗剂的用途。
• NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：US20170066772A1

  公开（公告）日：2017-03-09

  An object to be solved by the present invention is to provide a novel pyrrolopyrimidine compound or a salt thereof having an NAE inhibitory action and a cell growth inhibitory effect. The present invention provides a compound or a salt thereof represented by Formula (A), as well as an NAE inhibitor, a pharmaceutical composition, and an antitumor agent comprising the compound or a salt thereof as an active ingredient.

  本发明要解决的问题是提供一种具有NAE抑制作用和细胞生长抑制作用的新型吡咯吡嘧啶化合物或其盐。本发明提供了由化学式（A）表示的化合物或其盐，以及一种NAE抑制剂、含有该化合物或其盐作为活性成分的药物组合物和抗肿瘤剂。
• [EN] THIAZOLIDIN-4-ONE AND [1,3]-THIAZINAN-4-ONE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS THIAZOLIDIN-4-ONE ET [1,3]-THIAZINAN-4-ONE COMME ANTAGONISTES DES RÉCEPTEURS À L'ORÉXINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2010131191A1

  公开（公告）日：2010-11-18

  The present invention relates to thiazolidin-4-one and [1,3]-thiazinan-4-one compounds of formula (I) wherein X, Y, R3 and R4 are as described in the description, or pharmaceutically acceptable salts thereof, for the prevention or treatment of diseases related to the orexin system. The present invention also relates to novel thiazolidin-4-one compounds of formula (II) and their use as pharmaceuticals, pharmaceutical compositions containing one or more compounds of formula (II), and especially their use as orexin receptor antagonists.

  本发明涉及式(I)的噻唑啉-4-酮和[1,3]-噻唑烷-4-酮化合物，其中X、Y、R3和R4如描述中所述，或其药学上可接受的盐，用于预防或治疗与促进素系统相关的疾病。本发明还涉及式(II)的新型噻唑啉-4-酮化合物及其作为药物的用途，含有一个或多个式(II)化合物的制药组合物，尤其是它们作为促进素受体拮抗剂的用途。
• THIAZOLIDIN-4-ONE AND [1,3]-THIAZINAN-4-ONE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS
  申请人：Aissaoui Hamed

  公开号：US20120088759A1

  公开（公告）日：2012-04-12

  The present invention relates to thiazolidin-4-one and [1,3]-thiazinan-4-one compounds of formula (I) wherein X, Y, R 3 and R 4 are as described in the description, or pharmaceutically acceptable salts thereof, for the prevention or treatment of diseases related to the orexin system. The present invention also relates to novel thiazolidin-4-one compounds of formula (II) and their use as pharmaceuticals, pharmaceutical compositions containing one or more compounds of formula (II), and especially their use as orexin receptor antagonists.

  本发明涉及式（I）的噻唑啉-4-酮和[1,3]-噻唑烷-4-酮化合物，其中X、Y、R3和R4如描述中所述，或其药学上可接受的盐，用于预防或治疗与促进醒觉系统有关的疾病。本发明还涉及式（II）的新型噻唑啉-4-酮化合物及其用作药物、含有一个或多个式（II）化合物的药物组合物，特别是它们作为促进醒觉受体拮抗剂的用途。